Overview

HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL

Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
The objective of this clinical study is to compare the safety and effectiveness of Valchlor versus HyBryte following 12 weeks of treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Soligenix
Treatments:
Hypericin
Mechlorethamine